MaxCyte Inc (NASDAQ:MXCT) reported fourth-quarter and full-year 2025 financial results that fell short of analyst expectations, leading to a negative after-hours reaction in its stock price. The company, a provider of cell-engineering platform technologies, also issued revenue guidance for 2026 that suggests a continued period of transition and challenges.
Earnings Versus Estimates
The company's reported figures for the final quarter of 2025 missed Wall Street's consensus targets on both the top and bottom lines. This shortfall appears to be the primary driver behind the stock's immediate decline following the announcement.
- Q4 2025 Revenue: MaxCyte reported revenue of $7.3 million. This came in significantly below the analyst estimate of approximately $9.59 million.
- Q4 2025 EPS: The company reported a non-GAAP loss per share of $0.06. This was a narrower loss than the estimated $0.08 per share loss anticipated by analysts.
For the full year 2025, total revenue was $33.0 million, a 15% decrease from the $38.6 million reported in 2024. The net loss for the year widened to $44.6 million from $41.1 million in the prior year.
Market Reaction and 2026 Outlook
Following the earnings release, MaxCyte's stock traded down nearly 4% in after-market activity. This negative price action reflects investor disappointment with the revenue miss and the company's forward-looking statements.
Management provided initial revenue guidance for the full year 2026, projecting a range of $30 million to $32 million. This forecast is notably lower than the current analyst consensus estimate for 2026 sales, which stands at approximately $39.2 million. The guidance incorporates what the company describes as a "$4 million core revenue headwind" from select Strategic Platform License (SPL) customers, including a 15% reduction from its largest client.
The company expects this headwind to stabilize in the second half of 2026. For the upcoming first quarter of 2026, analysts are currently estimating revenue of about $9.08 million and a loss per share of $0.06.
Key Takeaways from the Press Release
Beyond the headline numbers, management highlighted several strategic and operational points in their commentary:
- Customer Headwinds: CEO Maher Masoud explicitly cited challenges with select SPL partners as a drag on 2025 performance, a dynamic expected to persist into the first half of 2026.
- Cost Management: The company emphasized a reduction in annual cash burn by over $16 million and a streamlined cost structure in 2025.
- Platform Growth: MaxCyte continues to expand its SPL portfolio, signing four new agreements in 2025, bringing the total to 32. The company noted it expects to support up to four therapies in Phase III clinical trials by the end of 2026 and has already received a milestone payment for one.
- Strong Balance Sheet: The company ended 2025 with a robust cash position of $155.6 million in cash, cash equivalents, and investments. It expects to end 2026 with at least $136 million, providing a lengthy runway to navigate current challenges.
Financial Health and Metrics
A review of the company's key metrics reveals a mixed picture of foundational growth and near-term pressure:
- The installed base of instruments grew to 857, up from 760 at the end of 2024.
- Core revenue generated by SPL clients decreased to 47% of total core revenue, down from 55% in 2024.
- The number of licensed clinical programs under SPLs currently in the clinic decreased to 13 from 18 a year ago.
For a deeper dive into MaxCyte's historical earnings performance and to view future analyst projections and estimates, you can review the details here: MXCT Earnings and MXCT Analyst Forecasts.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation to buy or sell any security, or an endorsement of any investment strategy. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.